- 田文浩裝置藝術展9/22 敦煌藝術展 9/27
- 全美總會線上講座 - 如何申請進入理想的大學 10/8
- Boston Asian American Film Festival preview party 10/5, festival 10/19-22
- 波克萊台商賞楓 10/28 新英格蘭玉山科協年會11/4
- 紐英倫作協講座 10/19
- 招聘 - BCNC, 武漢大學10/14, 波士頓市府10/19
- 崇德佛院 普賢講堂 慈濟
- 紐英崙中華專業人員協會40週年 10/28 GBCCA年會 2/10
- 醫藥 - HMS deciphering the genome 10/12 首屆世界針灸康養大會12/2-7
- 留美華人企業家聯合會年會10/7 Under 30 Summit 10/1-4
- BCIC - Fintech Roundtable Brainstorming Session 10/9 醫療科技路演 10/13
- ILF 國際領袖基金會
- ILF 國際領袖基金會 - ACE Next generation conference 8/18-20
- MIT ENERGY CLUB Mass Innovation Nights
- MIPIM 2017 - Real Estate Tech Trends from MIPIM
- 麻州州長動態 - Visits Marlborough High School’s Early College Program
- 羅德島州克蘭斯頓市長馮偉傑 Car Tax Bill
- City of Boston, Quincy, Malden, Greenway 昆市市長亞裔顧問委員會
- 牛頓市議員馬惠美- council meeting notes 10/1
- 波士頓市議會議長吳弭 (Michelle Wu ) - fundraiser for Puerto Rico 10/14
- Ben Chin (陳樂) for Mayor in Maine - Signs were stolen
- BIOVision/ Boston MedTech / Mass Life Sciences
- 華人參政 - 牛頓市候選人論壇10/15
- Plays - Lost Tempo 10/5 OLEANNA 10/14-11/5 Elemeno Pea 11/2-19 無名劇社 11/26
- 博物館 - Guggenheim, Harvard Art, Forbes House, China Institute
- 劍橋市素描餐廳 10/6 試新菜
- 李保華忠告年輕人 做個遠大的夢
- 【你的學歷，能幫助公司什麼…？】如果沒有這 7 個特質，你讀到台大也沒用！
- 朱学渊 - 陈建奇、郭晓敏：特朗普重塑全球的三大战略
- 作者專欄： 王世輝 - 看見台灣：向齊柏林致敬
- 台灣工程師的矽谷故事- 兩份文件，與嫁衣台灣
星期三, 2月 24, 2016
Andrew Lo's Wall Street-style financial engineering could make life-saving cancer drugs more available and affordable
New research by MIT and Dana Farber shows how Wall Street-style financial engineering could make life-saving cancer drugs more available and affordable
Securitized consumer healthcare loans spread the cost of therapies over many years
Cambridge, Mass., February 24, 2016—At a time when breakthrough therapies for certain types of cancers, hepatitis C, and rare diseases exist but remain out of reach for many patients due to their prohibitive cost, new research* by MIT Sloan Prof. Andrew W. Lo, Dana-Farber Cancer Institute’s David Weinstock, MD, and MIT post-doctoral fellow Vahid Montazerhodjat offers a practical remedy: securitized consumer healthcare loans (HCLs). The team’s research is published today in Science Translational Medicine.
HCLs, the equivalent of mortgages for large healthcare expenses, spread the cost of drugs and curative therapies over many years, making them more affordable to the people who need them. Financing HCLs through securitization—a financial engineering technique that involves pooling loans and converting them into securities—would allow more patients to have access to the drugs while generating attractive returns to investors.
“This is an instance where financial engineering could benefit the entire ecosystem,” says Lo. “It helps patients by providing them with affordable access to therapeutic drugs and cures. It helps biopharmaceutical companies by enabling them to get paid back for the substantial investments in R&D they make to develop the therapies in the first place. And it helps insurance companies by linking payment to ongoing benefit.”
Scientists have recently developed several breakthrough cures for diseases, but often the medicine’s cost is stratospheric. Case in point: Glybera, a gene therapy that cures the highly rare disease lipoprotein lipase deficiency, was recently approved in Germany. Its price tag: nearly $1 million. The benefit from Glybera may last for the patient’s remaining lifetime but the entire cost is paid upfront.
“The stark reality is that many patients don’t have access to transformative therapies like Glybera solely due to affordability,” says Weinstock. “This is a problem that will only grow as scientists create more cures. In the next five to seven years we could see cures for diseases like ALS, Duchenne muscular dystrophy, and many types of cancer, but those therapies could be too expensive for the average patient.”
Securitized HCLs may also be profitable investments. Based on numerical simulations and statistical models, a large, diversified fund of HCLs generated hypothetical annual returns of 12%. For comparison, over the ten-year period from January 2006 to December 2015, the Standard & Poor’s 500 Index saw a compound annual return of only of 7.3%.
“As an investment, securitized HCLs have another important advantage—they are not likely to be highly correlated with the stock market,” says Lo. “This makes them even more attractive for investors such as pension funds, mutual funds, and life insurance companies.”
Lo and his co-authors acknowledge that using financial engineering techniques in healthcare is not without risk—especially as securitization was chief among the techniques that precipitated the recent global financial crisis. While securitization is actively used in many markets today and plays a critical role in financing mortgages, student loans, and consumer credit, it can still be abused if proper protections, including regulatory oversight, are absent.
“But to argue that securitization is simply ‘too risky’ without a reasonable alternative is to relegate patients in desperate need to the status quo,” says Lo. “Securitized HCLs make expensive breakthrough therapies more affordable right now. The science is here and it’s moving at breakneck speed. Now we need the financial models to catch up.”
* Vahid Montazerhodjat, David M. Weinstock, Andrew W. Lo. “Buying Cures vs. Renting Health: Financing Healthcare via Consumer Healthcare Loans.” Science Translational Medicine 24 Feb. 2016. Print.